HeartBeam, Inc. (BEAT) - 10-K Summary
Business Context and Reporting Period
Company: HeartBeam, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: HeartBeam is a medical technology company developing ambulatory cardiac monitoring solutions. Its core product, the HeartBeam System, is a credit-card-sized, cable-free device that captures heart electrical activity from three distinct directions. The company aims to synthesize a 12-Lead (12L) ECG for arrhythmia and ischemia detection outside of healthcare facilities.
Key Milestones:
- December 13, 2024: Received FDA 510(k) clearance for the initial HeartBeam System (3-lead collection).
- January 2025: Filed a second 510(k) notification for software algorithms to synthesize a 12L ECG from the collected signals.
- February 2025: Completed a public offering raising approximately $11.5 million in gross proceeds.
Key Financial Metrics
Note: All figures in thousands unless otherwise stated.
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(19,448) | $(14,639) |
| Operating Expenses | $19,887 | $15,314 |
| Cash and Cash Equivalents (Year End) | $2,377 | $16,189 |
| Net Cash Used in Operating Activities | $(14,471) | $(12,093) |
| Stock-Based Compensation | $4,299 | $3,208 |
Liquidity: As of December 31, 2024, the company held $2.4 million in cash. The company has an At-The-Market (ATM) sales agreement with approximately $16.2 million available for issuance as of year-end.
Material Changes vs. Prior Period
- Increased Losses: Net loss increased by 33% (from $14.6M to $19.4M) driven by higher operating expenses.
- R&D Spike: Research and Development expenses surged 63% to $11.1 million, primarily due to increased headcount ($1.8M), clinical study costs ($0.7M), and consulting/patent expenses ($1.0M).
- Cash Burn: Cash and cash equivalents decreased by $13.8 million (82% decline) due to operating losses and capital expenditures.
- Management Transition: Robert Eno was appointed CEO in October 2024, succeeding founder Branislav Vajdic, who became President. Timothy Cruickshank was appointed CFO in September 2024.
Outlook, Risks, and Contingencies
Going Concern Warning: The company's independent auditors have issued a "going concern" opinion, expressing substantial doubt about the company's ability to continue operations for the next twelve months without additional financing. Management believes existing cash (including proceeds from the February 2025 offering) is insufficient to fund operations for the next 12 months.
Guidance and Strategy:
- Commercialization: The company does not anticipate significant revenue until the 12L synthesis algorithm receives FDA clearance. An Early Access Program is being initiated to gather real-world feedback.
- Capital Needs: The company explicitly states it requires additional capital to support its business plan and growth. Future financing may be dilutive.
Key Risks:
- Regulatory: Failure to obtain clearance for the 12L synthesis software would prevent commercialization of the full product suite.
- Reimbursement: Uncertainty regarding third-party payer reimbursement for ambulatory cardiac monitoring services.
- Competition: Intense competition from established players (Apple, AliveCor, iRhythm) and larger medical device companies.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $11.5M raised in February 2025 combined with remaining cash to fund operations until the next anticipated revenue stream.
- 12L Clearance Timeline: Monitor the FDA review status of the January 2025 510(k) submission for the 12L synthesis software, which is critical for revenue generation.
- Dilution Risk: Assess the impact of the ATM facility ($16.2M remaining) and potential future equity raises on existing shareholder ownership.
- Reimbursement Strategy: Evaluate the company's progress in securing payer contracts or establishing reimbursement codes for the device.
- Internal Controls: Note that while material weaknesses in internal controls were remediated as of Dec 31, 2024, the company remains an Emerging Growth Company with reduced reporting requirements.